Surescripts and Diameter Health Partner to Enhance Clinical Intelligence

Surescripts and Diameter Health Partner to Enhance Clinical Intelligence

What You Should Know:

Surescripts and Diameter Health are partnering to simplify specialty prescribing by incorporating powerful clinical intelligence and standardizing patient data to communicate comprehensive patient histories.


Surescripts has simplified the specialty prescribing and fulfillment process to help specialty pharmacies and physician practices realize decreased phone calls, increased dispense rates and improvements in time to therapy. Now, Surescripts is expanding its clinical intelligence capabilities by partnering with Diameter Health to provide timely, easily accessible and accurate patient data for specialty pharmacies.

Empowering Specialty Pharmacists with EHR-Integrated Data

Through the partnership, Diameter Health will generate interoperable, enriched and actionable data from electronic health records (EHRs) empowering specialty pharmacists with the information they need to fill medications. Surescripts will then make that data available through the Specialty Medications Gateway, a platform that automates the collection and delivery of clinical information for specialty pharmacies leaving pharmacists more time to counsel patients and fill scripts.

Specialty Medications Gateway compliments Surescripts Specialty Patient Enrollment which is used by prescribers to automate the specialty enrollment process with patient data sent directly from the EHR to the specialty pharmacy or hub.

“Surescripts is focused on reducing the time it takes to get patients needing specialty medications onto their therapy,” explained Mike Pritts, Chief Product Officer at Surescripts. “As we innovate in this area, we are excited to partner with Diameter Health to deliver enhanced clinical intelligence for specialty pharmacies. By providing fast and easy access to simple-to-understand, normalized, patient-centric clinical data, we can help providers avoid the back-and-forth phone calls and faxes that slow the approval of specialty therapies and ultimately delay treatments.”